Human adjuvant disease (HAD), first described by Miyoshi in 1973, is associated with exposure to foreign substances that can act as adjuvants, some of which are injected into patients for cosmetic purposes, including silicone, mineral oil, guaiacol, and others [1]. The incidence and prevalence of HAD keep on increasing and over one million persons in Latin America have become victims of these substances [2]. Human adjuvant disease is associated with the exposure to foreign substances that act as foreign bodies (adjuvants), some of which are injected into patients for cosmetic purposes, including silicone, mineral oil, guaiacol, and others. A new term - autoimmune/inflammatory syndrome induced by adjuvants has recently been coined with a process that includes several clinical features previously described by Miyoshi plus other clinical and laboratory parameters related to exposure to diverse external stimuli. Disorders such as silicosis, Gulf War syndrome, macrophagic myofascitis syndrome, sick building syndrome, and post-vaccination syndrome have been included in autoimmune/inflammatory syndrome induced by adjuvants. Disorders such as Spanish toxic oil syndrome and Ardyhist syndrome could also be included [3].

The standard management starts with pharmacological therapy based on non-steroidal anti-inflammatory drugs, analgesics, and low or moderate doses of prednisone and immunosuppressor drugs, for example, azathioprine or chloroquine; when there is an improvement of the clinical manifestations, they proceed to surgical excision totally or partially and surgical reconstruction.

In Mexico, Dr. Fernando Ortiz Monasterio (Department of Plastic Surgery, General Hospital in Mexico) created an algorithm with multidisciplinary management (Figure 1), expanding the knowledge of the natural history of the disease, the proper medical and surgical treatment, as well as its prognosis [4]. It was a systematic management protocol including 504 patients, of which, 128 patients received surgical treatment, including 40 (31.25%) male and 88 (68.75%) female. In 86 of the cases, the substances were injected into the buttock, 23 cases in breasts, 11 cases in legs or/and thighs, and 8 cases in the facial area. They made diagnoses with a skin biopsy, Magnetic resonance imaging, and chest X-ray. A multidisciplinary approach with rheumatology, psychiatry, and plastic surgery was performed to decide if the patient was a candidate for a reconstructive procedure or conservative treatment (Figure 2).

In this article, we presented 3 cases of lower extremities HAD treated by the extensive excision and reconstructed with the free flap with good results including one case diagnosed with chronic fatigue syndrome and severe skin adjuvant infiltration, and 2 patients including skin ulcers. The aggressive debridement and complete removal of foreign materials were mandatory to control the disease, and reconstructed with an indocyanine green (ICG) designed free flap can assure the stable wound coverage. Post-operative follow-up thermograms were performed and no complications were found. A multidisciplinary approach, including rheumatology, psychiatry, and plastic surgery, is an essential component of providing optimal care to HAD patients. Complete removal of foreign materials is considered the gold standard to diminish the immune reaction against the adjuvant, and a proper reconstruction to guarantee stable coverage with no relapses of disease and a good aesthetic result.

INTRODUCTION

Human adjuvant disease (HAD) is associated with exposure to foreign substances that are injected into patients for cosmetic purposes including silicone, mineral oil, guaiacol, and others. The incidence and prevalence of HAD keep increasing. The standard management of HAD starts with pharmacological therapy based on non-steroid anti-inflammatory drugs, analgesics, and low or moderate doses of prednisone and immunosuppressor drugs. When clinical improvement is achieved, surgical excision is made along with surgical reconstruction. This article presented 3 cases diagnosed with chronic fatigue syndrome, severe skin adjuvant infiltration and skin ulcers. The aggressive debridement and complete removal of foreign materials were performed, and the reconstruction with an intra-operative indocyanine green designed free flap was made to assure stable wound coverage. Post-operative follow-up thermograms were performed and no complication was found. A multidisciplinary approach, including rheumatology, psychiatry, and plastic surgery, is an essential component of providing optimal care to HAD patients. Complete removal of foreign materials is considered the gold standard to diminish the immune reaction against the adjuvant, and a proper reconstruction to guarantee stable coverage with no relapses of disease and a good aesthetic result.
Figure 1. Dr. Fernando Ortiz Monasterio department approach of human adjuvant disease.
Figure 2. Surgical management of human adjuvant disease according to the affected body area.
Table 1. Case Reports and Literature Review

| Study                        | Number of cases | Treatment                                                                 | Complications                                                                 |
|------------------------------|-----------------|---------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Kumagai et al., 1979 [5]     | 9               | 8 pharmacological therapy; 1 bilateral mastectomy                         | Not specified                                                                |
| Brozena et al., 1988 [6]     | 2               | 1 pharmacological; 1 bilateral Mastectomy                                  | Partial necrosis flap                                                        |
| Torres et al., 2010 [7]      | 110             | 15 pharmacological therapy; 95 surgical resection ad direct closure vs. microsurgery (TRAM, DIEP, latissimus dorsi flap, lumbar perforator flaps) | 2 deaths; 6 partial or total suffer of nipple-areola complex                  |
| Torres et al., 2010 [7]      | 279             | Not specified                                                             | Not specified                                                                |
| Vera-Lastra et al., 2012 [8] | 50              | 50 pharmacological therapy; 40 surgical resection                         | 20 depression; 8 severe autoimmune disease; 4 deaths                         |
| Gordillo-Hernández et al., 2013 [3] | 504 | 376 pharmacological therapy; 128 surgical resection and direct closure vs. microsurgery | Not specified                                                                |
| Wataad et al., 2017 [9]      | 300             | 107 glucocorticoids; 57 DMARD; 4 biological treatment; 3 etarnercept; 1 infliximab; 15 intravenous immunoglobulin | Not reported                                                                 |

DIEP, deep inferior epigastric artery perforator; DMARD, disease-modifying antirheumatic drug; TRAM, transverse rectus abdominis myocutaneous.

Figure 3. Bilateral thighs with a 15x5 cm tumor on the distal lateral right thigh. The tumor was well defined, associated with edema, erythema, skin induration, and hyperpigmentation.

Figure 4. En block resection of infiltrated skin and bilateral final defects of case 2.

Figure 5. Fluorescence technology using green indocyanine for perfusion assessment during surgery and the final result of the abdominal wall. (A) Harvest of deep inferior epigastric perforator flap. (B) Perfusion assessment of the flaps using green indocyanine. (C) Final result of the abdominal wall.

Figure 6. Bilateral lower legs with skin infiltration, erythema, and skin induration. An 3x3 cm ulcer was located on the left lower leg with exposed adjuvant and soft tissue.
months ago, she noted an ulcer at the left lower leg. The systemic symptoms included chronic fatigue, myalgia, and arthralgia. The physical examination revealed a 13x8 cm well-defined infiltrated and erythematous area at bilateral distal lower legs. The left field presented with a 3x3 cm ulcer (Figure 6). MRI of the legs revealed hyperintensity areas in the subcutaneous tissue located in the bilateral calves without muscle involvement. After the en bloc resection of the involved area of the necrotic and inflammatory tissue until muscular fascia, the skin and soft tissue defect of 14x9 cm with exposure of bilateral tibia were noted bilaterally (Figure 7). Because of the previous anterior abdominal wall liposuction history, in this case, bilateral anterolateral thigh (ALT) flaps were designed and harvested for the defect coverage and repaired the anterior tibial vessels. The post-operative monitoring was done by clinical examination; doppler signal and SEEK thermographic camera as an adjunctive tool; no complications recorded. The patient discharged on post-op day 5 with no need for further medical treatment for HAD. The six months follow-up (Figure 8) revealed a satisfactory functional and aesthetic outcome.

**Case 3**
A 59 years old female had a history of mineral oil injection 45 years ago at bilateral lower legs for calf augmentation. She had severe skin infiltration and ulceration at both lower legs 18 years ago, which was managed initially with skin grafts. At the left lower leg, she required a soleus muscular flap and skin graft to cover an ulcer 14 years ago. She then had multiple relapses of the ulcer and it was managed conservatively. Unfortunately, a severe relapse of this ulcer occurred and over infection with pseudomonas developed a major ulcer. Systemic symptoms included as previous patients. The physical exam revealed a well delimitated 15x9 cm ulcer at the lower left leg, with ill granulation tissue, exposure of adjuvant at the borders of ulcer, and moderate exudative fluid. Tissue cultures revealed pseudomonas aeruginosa, managed with Zavicefta (ceftazidime/avibactam).

After en bloc resection of ulcer, granulation tissue, and foreign materials until tendons and bone with free margin, the tissue defect was measured 20x11 cm with exposure of tibia. Since the patient also had the previous history of a tummy tuck, an ALT flap was designed and harvested for wound coverage and repaired the anterior tibial vessels under magnification.

The post-operative follow-up was made clinically and by thermography with FLIR One thermographic camera as an adjunctive tool, and no complications recorded. The patient discharged on the third post-operative day. After two months, the patient revealed a satisfactory functional outcome. Unfortunately, the other leg was still infiltrated with mineral oil, and this was the main reason she was still on treatment for HAD.

**DISCUSSION**
Surgical treatment in HAD continues to be a challenge, and it is arising in the Latin American population with a report of more than one million people affected. However, nowadays, there are still few reports of surgical management for this disease (Table 1). It is considered that the full removal of adjuvants would improve the symptoms and local conditions of the affected patients. With the experienced microsurgical reconstruction, we can guarantee the removal of 100% of the foreign body in the region with proper wound coverage.

An ICG designed flap can guarantee a well-defined vascularized flap, with no necrotic edges or wound problems as dehiscence that are common in patients with infiltration of adjuvants (due to dermis infiltrated or long last use of steroids). Also, the postoperative follow-up with thermographic cameras is a handy and economical tool to decrease the need for a specialized nurse or doctor.

Nowadays, with microsurgical advances, the reconstruction of defects arising after resection in a block of the affected tissue, due to the infiltration of modeling substances, is becoming worldwide accepted, especially in a patient with severely impaired quality of life. Multidisciplinary management, including rheumatology service, can improve the quality of life of this kind of patient.
CONCLUSION

The complete removal of foreign material is the gold standard to diminish the immune reaction against the adjuvant, and proper reconstruction guarantees stable coverage with no relapses of the disease, better control of the immunologic response, and an acceptable functional and aesthetic result.

ARTICLE INFORMATION

*Correspondence: Javier López Mendoza, MD, MBA, FACS. Department of Plastic Surgery, Hospital Ángeles del Pedregal, Camino de Sta. Teresa 1055-S, Heroes de Padierna, Héroes de Padierna, La Magdalena Contreras, 10700 Ciudad de México, CDMX, Mexico

Received: Jan. 16, 2020; Accepted: May 13, 2020; Published: Dec. 09, 2020

DOI: 10.24983/scitemed.imj.2020.00138

Ethics Approval and Consent to Participate: The study is in accordance with the ethical standards of the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Funding: The study did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of Interest: The authors report no financial or other conflict of interest relevant to this article, which is the intellectual property of the authors.

Copyright © 2020 The Authors. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY).

REFERENCES

1. Torres GB, Burgos VR, Medrano RG, Priego BRB: Instrumento para evaluar y estadificar el daño producido por la infiltración de sustancias modelantes. Cir Plast 2010;20(3):105-111.
2. Colffman F. A new disease: iatrogenical alogenosis. Cir plást iberolatinoam 2008;34(1):1-10.
3. Gordillo-Hernández J, Alegre-Tamez E, Torres-Baltazar I, Mendiesta-Espinosa Mj, Sastre-Ortiz N. Multidisciplinary management of adjuvant human disease by injection of modeling substances. Cir plást iberolatinoam 2013;39(3):269-277.
4. Aljotas-Reig J. Human adjuvant-related syndrome or autoimmune/inflammatory syndrome induced by adjuvants. Where have we come from? Where are we going? A proposal for new diagnostic criteria. Lupus 2015;24(10):1012-1018.
5. Kumagai Y, Abe C, Shiokawa Y. Scleroderma after cosmetic surgery: four cases of human adjuvant disease. Arthritis Rheum 1979;22(5):532-537.
6. Brozena Sj, Fenske NA, Cruse OW, et al. Human Adjuvant Disease Following Augmentation Mammaplasty, Arch Dermatol 1988;124(9):1383-1386.
7. Torres GB, Medrano RG, Priego BR, Peláez Bi, Burgos VR. Enfermedad por la infiltración de sustancias modelantes con fines estéticos. Cir Plast 2010;20(3):124-132.
8. Vera-Lastra O, Medina G, Cruz-Dominguez MP, et al. Human adjuvant disease induced by foreign substances: a new model of ASIA (Shoenfeld's syndrome). Lupus 2012;21(2):128-135.
9. Watad A, Quresma M, Bragazzi NL, et al. The autoimmune/inflammatory syndrome induced by adjuvants (ASIA)/Shoenfeld's syndrome: descriptive analysis of 300 patients from the international ASIA syndrome registry. Clin Rheumatol 2018;37(2):483-493.